Sorafenib In Relapse of FMS-like Tyrosine Kinase 3 (FLT3)-Internal Tandem Duplication (ITD) AML Trial

计划入组 396 人 · 首次发布于 2016 年 8 月 16 日

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

计划入组 276 人 · 首次发布于 2017 年 6 月 9 日

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

计划入组 33 人 · 首次发布于 2020 年 12 月 31 日

EYD-002

FMS like tyrosine kinase 3 inhibitor(TargetRx)

Albumin-FMS-like tyrosine kinase 3 ligand

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

Robust AML Clinical Pipeline Shows Promise with 100+ Companies Developing Novel Therapies

Invivoscribe's LabPMM Secures New York State Approval for Ultra-Sensitive FLT3 ITD MRD Assay in AML

ASCO 2025 Showcases Advances in Myelofibrosis Treatment with Novel JAK Inhibitors and Personalized Approaches